nach oben

Breast Cancer Research

Erschienen in:

01.12.2007 | Letter

Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?

verfasst von: April AN Rose, Peter M Siegel

Erschienen in: Breast Cancer Research | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Excerpt

In the previous issue of Breast Cancer Research, Metz and colleagues characterize hematopoietic growth factor inducible neurokinin-1 type (HGFIN; osteoactivin, Gpnmb, Dc-HIL) as a gene expressed in normal mammary epithelial cells that encodes a protein with tumor suppressor functions in breast cancer [1]. In contrast, we have recently identified osteo-activin as a novel mediator promoting breast cancer metastasis [2] and thus feel it is premature to classify osteoactivin as a tumor suppressor in breast cancer. …

Metz RL, Patel PS, Hameed M, Bryan M, Rameshwar P: Role of human HGFIN/nmb in breast cancer. Breast Cancer Res. 2007, 9: R58-10.1186/bcr1764.CrossRefPubMedPubMedCentral

Rose AAN, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res. 2007, 5: 1001-1014. 10.1158/1541-7786.MCR-07-0119.CrossRefPubMed

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.CrossRefPubMedPubMedCentral

Oncomine – Cancer Profiling Database. [http://www.oncomine.org]

Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan C-T, Bigner DD, Counter CM, Wang X-F: Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem. 2003, 278: 15951-15957. 10.1074/jbc.M211498200.CrossRefPubMed

Weterman MA, Ajubi N, van Dinter IM, Degen WH, van Muijen GN, Ruitter DJ, Bloemers HP: nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995, 60: 73-81. 10.1002/ijc.2910600111.CrossRefPubMed

Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, et al: CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res. 2006, 12: 1373-1382. 10.1158/1078-0432.CCR-05-2018.CrossRefPubMed

Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, et al: Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007, 60: 423-435. 10.1007/s00280-007-0490-z.CrossRefPubMed

Titel: Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?
verfasst von: April AN Rose
Peter M Siegel
Publikationsdatum: 01.12.2007
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 6/2007
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1791

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases

Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer

Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer

Breast tumour angiogenesis

Adjuvant endocrine therapy for premenopausal women with early breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie